Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.

Kwakman JJM, Baars A, van Zweeden AA, de Mol P, Koopman M, Kok WEM, Punt CJA.

Eur J Cancer. 2017 Aug;81:130-134. doi: 10.1016/j.ejca.2017.05.022. Epub 2017 Jun 15. No abstract available.

PMID:
28623776
2.

Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.

Kwakman JJ, Simkens LH, Mol L, Kok WE, Koopman M, Punt CJ.

Eur J Cancer. 2017 May;76:93-99. doi: 10.1016/j.ejca.2017.02.009. Epub 2017 Mar 10.

PMID:
28286287
3.

Editorial commentary: Biomarkers in heart failure, between scientific scrutiny and exploration.

Kok WE.

Trends Cardiovasc Med. 2017 Feb;27(2):134-135. doi: 10.1016/j.tcm.2016.08.004. Epub 2016 Aug 11. No abstract available.

PMID:
27666742
4.

Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients.

Stienen S, Salah K, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Tijssen JP, Pinto YM, Kok WE.

JACC Heart Fail. 2016 Sep;4(9):736-45. doi: 10.1016/j.jchf.2016.05.007. Epub 2016 Jul 6.

PMID:
27395353
5.

Reply: Worsening Renal Function in Acute Decompensated Heart Failure: The Puzzle is Still Incomplete.

Salah K, Kok WE, Pinto YM.

JACC Heart Fail. 2016 Mar;4(3):233-4. doi: 10.1016/j.jchf.2015.12.002. No abstract available.

PMID:
26940629
6.

Competing Risk of Cardiac Status and Renal Function During Hospitalization for Acute Decompensated Heart Failure.

Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Verdiani V, Tijssen JG, Pinto YM.

JACC Heart Fail. 2015 Oct;3(10):751-61. doi: 10.1016/j.jchf.2015.05.009.

PMID:
26449995
7.

Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis.

Salah K, Pinto YM, Eurlings LW, Metra M, Stienen S, Lombardi C, Tijssen JG, Kok WE.

Am Heart J. 2015 Sep;170(3):531-42.e1. doi: 10.1016/j.ahj.2015.06.003. Epub 2015 Jun 10.

PMID:
26385037
8.

Nutrition before and during Surgery and the Inflammatory Response of the Heart: A Randomized Controlled Trial.

Visser M, Niessen HW, Kok WE, Cocchieri R, Wisselink W, van Leeuwen PA, de Mol BA.

J Nutr Metab. 2015;2015:123158. doi: 10.1155/2015/123158. Epub 2015 Jul 29.

9.

Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?

Stienen S, Salah K, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Tijssen JP, Pinto YM, Kok WE.

Eur J Heart Fail. 2015 Sep;17(9):936-44. doi: 10.1002/ejhf.320. Epub 2015 Jul 29.

10.

N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment.

Stienen S, Salah K, Dickhoff C, Carubelli V, Metra M, Magrini L, Di Somma S, Tijssen JP, Pinto YM, Kok WE.

J Card Fail. 2015 Nov;21(11):930-4. doi: 10.1016/j.cardfail.2015.07.011. Epub 2015 Jul 26.

11.

Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE.

JAMA Intern Med. 2015 Jun;175(6):1007-17. doi: 10.1001/jamainternmed.2015.1180.

PMID:
25915855
13.

Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study.

van der Pal HJ, van Dijk IW, Geskus RB, Kok WE, Koolen M, Sieswerda E, Oldenburger F, Koning CC, van Leeuwen FE, Caron HN, Kremer LC, van Dalen EC.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):213-22. doi: 10.1016/j.ijrobp.2014.09.010. Epub 2014 Oct 25.

PMID:
25442333
14.

Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance.

Smid BE, Hollak CE, Poorthuis BJ, van den Bergh Weerman MA, Florquin S, Kok WE, Lekanne Deprez RH, Timmermans J, Linthorst GE.

Clin Genet. 2015 Aug;88(2):161-6. doi: 10.1111/cge.12449. Epub 2014 Sep 5.

PMID:
25040344
15.

Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes.

Stienen S, Salah K, Moons AH, Bakx AL, van Pol PE, Schroeder-Tanka JM, Voogel AJ, Keijer JT, Kortz RA, Dickhoff C, Meregalli PG, Tijssen JG, Pinto YM, Kok WE.

Am Heart J. 2014 Jul;168(1):30-6. doi: 10.1016/j.ahj.2014.04.008. Epub 2014 Apr 23.

PMID:
24952857
16.

Nutrition before, during, and after surgery increases the arginine:asymmetric dimethylarginine ratio and relates to improved myocardial glucose metabolism: a randomized controlled trial.

Visser M, Davids M, Verberne HJ, Kok WE, Tepaske R, Cocchieri R, Kemper EM, Teerlink T, Jonker MA, Wisselink W, de Mol BA, van Leeuwen PA.

Am J Clin Nutr. 2014 Jun;99(6):1440-9. doi: 10.3945/ajcn.113.075473. Epub 2014 Apr 2.

17.

A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.

Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Damman P, Tijssen JG, Pinto YM.

Heart. 2014 Jan;100(2):115-25. doi: 10.1136/heartjnl-2013-303632. Epub 2013 Oct 31.

18.

Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.

de Peuter OR, Verberne HJ, Kok WE, van den Bogaard B, Schaap MC, Nieuwland R, Meijers JC, Somsen GA, Bakx A, Kamphuisen PW.

J Nucl Med. 2013 Oct;54(10):1733-9. doi: 10.2967/jnumed.113.120477. Epub 2013 Aug 22.

19.

High risk of symptomatic cardiac events in childhood cancer survivors.

van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, Sieswerda E, Oldenburger F, Koning CC, van Leeuwen FE, Caron HN, Kremer LC.

J Clin Oncol. 2012 May 1;30(13):1429-37. doi: 10.1200/JCO.2010.33.4730. Epub 2012 Apr 2.

PMID:
22473161
20.

The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors.

Sieswerda E, Postma A, van Dalen EC, van der Pal HJ, Tissing WJ, Rammeloo LA, Kok WE, van Leeuwen FE, Caron HN, Kremer LC; Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology Group (DCOG LATER).

Ann Oncol. 2012 Aug;23(8):2191-8. Epub 2012 Feb 6.

PMID:
22312159

Supplemental Content

Loading ...
Support Center